No Data
No Data
No Data
Tsubota Lab---TLG-005 Parkinson's Disease Project with Sumitomo Pharma Finished
Tsubota Lab <4890> announced on the 22nd that it will cancel the exclusive licensing rights relating to TLG-005 Parkinson's disease with Sumitomo Pharma <4506>. The company and Sumitomo Pharma have been proceeding with discussions for future commercialization studies based on the results of non-clinical research on TLG-005 Parkinson's disease and specific clinical research conducted by the company. No serious adverse events occurred in specific clinical studies, and certain effects were confirmed in terms of treatment effects, but Sumitomo Pharma identified this time
Tsubota Lab, Birdmane, etc.
<3224>Transfer all shares held by G Oyster consolidated subsidiary G.O. Farm to Goodfield, which handles the acquisition and holding of shares <4564>number of shares issued from 1 day of mass exercise of OTS 36th stock acquisition rights (with exercise price correction clauses), 9.7 million shares <4890>Tsubota Lab Sumitomo Pharma <4506> and TLG-005 dissolves exclusive licensing rights related to Parkinson's disease <7063>Birdman product sales system business Acquire ADOLOGI shares
Tsubota Lab --- Mr. Tsubota and related research team presented 16 topics at the 6th Annual Meeting of the Japanese Society of Myopia
Tsubota Lab <4890> announced on the 20th that CEO Tsubota Kazuo and related research teams presented 16 topics at the 6th Annual Meeting of the Japanese Myopia Society to be held at the Station Conference Tokyo from 18th to 19th. The company and a group of cooperating research institutes are proceeding with research and development related to preventing myopia and suppressing progression. The society promotes academic research on the pathogenesis and treatment of myopia and pathological myopia, and promotes prevention of blindness due to myopia
Tsubota Lab---Achieved the milestone of the license agreement even though sales declined for the fiscal year ending March 24
Tsubota Lab <4890> announced financial results for the fiscal year ending 2024/3 on the 13th. Net sales decreased 29.5% from the previous fiscal year to 673 million yen, operating loss was 649 million yen (profit of 167 million yen in the same period last year), ordinary loss was 636 million yen (profit of 144 million yen), and net loss was 641 million yen (profit of 90 million yen). In research and development, we will continue basic research to discover new intellectual property and add new pipelines, derive intellectual property, and research and development with partner companies that are joint research destinations
Tsubota Laboratory: Financial results presentation materials for the fiscal year ending March 31, 2024
Tsubota Laboratory: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Unconsolidated)
No Data